article Open AccessTop 1% cited

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

Clinical Pharmacology & Therapeutics · 2014 · Vol. 96(4) · pp. 423–428

Laura B. Ramsey✉(St. Jude Children's Research Hospital)Samuel G. Johnson(University of Montana)Kelly E. Caudle(St. Jude Children's Research Hospital)Cyrine E. Haidar(St. Jude Children's Research Hospital)Deepak Voora(Duke University)Russell A. Wilke(University of North Dakota)Whitney D. MaxwellHoward L. McLeod(Moffitt Cancer Center)Ronald M. KraussD M Roden(Vanderbilt University)QiPing Feng(Vanderbilt University)Rhonda M. Cooper‐DeHoff(University of Florida)Li Gong(Palo Alto University)Teri E. Klein(Palo Alto University)Mia Wadelius(Science for Life Laboratory)Mikko Niemi(King Abdulaziz University)

View via DOI Full-text PDF

Abstract

Simvastatin is among the most commonly used prescription medications for cholesterol reduction. A single coding single-nucleotide polymorphism, rs4149056T>C, in SLCO1B1 increases systemic exposure to simvastatin and the risk of muscle toxicity. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for simvastatin based on SLCO1B1 genotype. This article is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1 and simvastatin-induced myopathy.

Lipoproteins and Cardiovascular Health Genomics and Rare Diseases Health Systems, Economic Evaluations, Quality of LifeSLCO1B1SimvastatinPharmacogeneticsMyopathyGuidelineMedicineStatinSingle-nucleotide polymorphismPharmacologyMedical prescription

MeSH terms

Drug InteractionsGenotypeHumansMuscular DiseasesPharmacogeneticsPolymorphism, GeneticHydroxymethylglutaryl-CoA Reductase InhibitorsSimvastatinOrganic Anion TransportersLiver-Specific Organic Anion Transporter 1

Citations

439

FWCI

32.56

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Benefits and limitations of genome-wide association studies